McGill.CA / Cancer Prevention / Publications / Dr. Pollak's publications

2000 - 2001

2001

  1. Jernström H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, Hudson T, Narod SA, Pollak M. Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in healthy premenopausal women.Cancer Epidemiol Biomarkers Prev. 10: 377-84, 2001
  2. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M. Novel promoter polymorphism in IGFBP3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 86: 1274-80, 2001
  3. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M., Narod SA. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab. 72:144-54, 2001
  4. Trojan DA, Collet J, Pollak MN., Shapiro S, Jubelt B, Miller RG, Agre JC, Munsat TL, Hollander D, Tandan R, Robinson A, Finch L, Ducruet T, Cashman N. Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. J Neurol Sci. 182:107-15, 2001
  5. Pollak M. Insulin-like growth factors and prostate cancer. Epidemiol Rev. 23;1: 59-66, 2001
  6. Chokkalingam AP, McGlynn KA, Gao YT, Pollak M,Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res. 61: 4333-6, 2001
  7. Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: Rationale and current status as chemopreventive agents. Urology. 57:86-9, 2001
  8. Pollak M, Blouin M-J, Jian-Chun Z, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer. 85: 428-30, 2001
  9. Chokkalingam AP, Pollak M, Fillmore C, Gao Y, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and prostate cancer: a population-based cased-control study in China. Cancer Epidemiol Biomarkers Prev. 10:421-7, 2001
  10. He B, Deckelbaum RA, Miao D, Lipman ML, Pollak M, Goltzman D, Karaplis AC. Tissue-specific targeting of the pthrp gene: the generation of mice with floxed alleles. Endocrinology. 142: 2070-7, 2001.
  11. Nickerson T, Chang F, Tran C, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo of LAPC-9 and LNCaP cancer models to androgen independence is associated with increased expression of IGF-I and IGF-IR. Cancer Res. 61: 6276-80, 2001.
  12. Thorner M. and writing committee (including Pollak M). Critical evaluation of the safety of recombinant human growth hormone administration: statement from the growth hormone research society. Journal of Clinical Endocrinology & Metabolism. 86: 1868-70, 2001.
  13. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik Y, Li YW, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 10: 861-8, 2001.
  14. Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clin Cancer Res. 7: 2545-54, 2001.
  15. Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk intake, circulating levels of insulin like growth factor-I and risk of colorectal cancer in men. J Natl Cancer Inst. 93: 1330-6, 2001.
  16. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst, 93: 1852-7, 2001. [see also favorable editorial comment- J Natl Cancer Inst. 93: 1830-2, 2001].

TOP OF PAGE

2000

  1. Huynh H, Beamer W, Pollak M, Chan T. Modulation of transforming growth factor beta 1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol 16: 277-81, 2000
  2. Miyake H, Pollak M, Gleave M. Castration-induced up-regulation of IGFBP-5 potentiates IGF-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res. 60: 3058-64, 2000
  3. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod S, Bégin L. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol. 3: 307-13, 2000
  4. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev. 9: 345-9, 2000
  5. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-8, 2000
  6. Platz EA, Pollak MN, Willett WC, Giovannucci E. Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. J Am Acad Dermatol. 42: 1003-7, 2000
  7. Wilkin F, Paquette J, Ledru E, Mamelin C, Pollak M, Deal CL. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem. 267: 4020-7, 2000
  8. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF)I, IGF-binding protein 3, and mammographic density. Cancer Res. 60: 3744-8, 2000
  9. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60: 5617-20, 2000
  10. Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Hormone IGF Res 10 Suppl B: 21-4, 2000
  11. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrazole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-67, 2000
Back to top